AUS Edition 
NZ Edition 
UK Edition 
CA Edition 
USA Edition 
FRA Edition 
GER Edition 
ESP Edition 
ITA Edition 
NLD Edition 
PRT Edition 
SWE Edition 
GRC Edition 
IND Edition 
POL Edition 
BRA Edition 
ZAF Edition 
RUS Edition 
CHN Edition 
UAE Edition 
⚠
✓
Xvivo Perfusion AB (LSE:0RKL)
459.6985 GBP
+0.199 0.043%Sponsored Reports
Loading...
| Previous Close (in GBP) | 459.5 |
|---|---|
| Change | +0.199 0.043% |
| 52 W H/L (in GBP) | 333.000/178.200 |
| EBITDA (in GBP) | 44.297M |
| PE Ratio | 13.41 |
| Volume | 1586 |
| Diluted Eps TTM | 0.24 |
| Total Assets (in GBP) | 1733.084M |
|---|---|
| Total Liabilities (in GBP) | 302.948M |
| Revenue TTM (in GBP) | 573.316M |
| Cash (in GBP) | 246.545M |
| Market Cap (in GBP) | 84.182 M |
| Revenue Per Share TTM | 19.208 |
| Gross Profit TTM (in GBP) | 296.956M |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
Xvivo Perfusion AB
Xvivo Perfusion AB (publ), a medical technology company, develops solutions for organ, tissue, and cell preservation and perfusion in connection with transplantation in Sweden, the United States, North America and South America, Europe, the Middle East, Africa, and the Asia Pacific. The company offers XVIVO System (XPS), an integrated off-the-shelf cardiac bypass system that includes various components needed to safely run normothermic ex vivo lung perfusion (EVLP); XPS Disposable Lung Kit that contains disposables and pre-packed products to suit requirement for sterility; and STEEN Solution, a buffered extracellular solution optimally designed to perfuse the isolated donor lung during EVLP. It also provides Perfadex Plus, an extracellular, low potassium, dextran-based electrolyte preservation solution; XVIVO Silicone Tubing Set for rapid flushing of donor lungs during procurement; and XVIVO LS and XVIVO Disposable Lung Set, a device for EVLP. In addition, the company offers XVIVO Organ Chamber, a single-use sterile disposable container intended to be used as a temporary receptacle for isolated lungs in preparation for eventual transplantation into a recipient; and XVIVO Lung Cannula Set, a single-use, sterile disposable product. The company was incorporated in 1998 and is headquartered in Gothenburg, Sweden.
Employees: 144
Key Executives
| Sr. No. | Name | Title | Year Born |
|---|---|---|---|
| 1. | Mr. Christoffer Rosenblad | Chief Exec. Officer | 1975 |
| 2. | Mr. Kristoffer Nordstrom | CFO & Investor Relations | 1985 |
| 3. | Ms. Lena Hagman B.Sc. | Chief Operating Officer | 1965 |
| 4. | Dr. Magnus Nilsson Ph.D. | Sr. Advisor | 1956 |
| 5. | Ms. Katrin Gisselfalt Ph.D. | Global Quality Assurance & Regulatory Affairs Director | 1969 |
| 6. | Mr. Andreas Wallinder M.D., Ph.D. | Chief Medical Officer | 1977 |
| 7. | Mr. Johan Holmstrom | Chief Commercial Officer | 1970 |
| 8. | Ms. Charlotte Walldal | Global R&D director | 1967 |
| 9. | Jaya Tiwari | VP Clinical and Regulatory Affairs | NA |
| 10. | Mr. Christer de Flon | Mang. | 1949 |
Peers
| Company | Change (GBP) | Price (GBP) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
|
0RIH
Alphabet Inc Class A |
0.000 0.000% | 196.2 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 |
|
0QFP
Gedeon Richter PLC |
+5435.850 107.854% | 10475.8496 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 |
|
0M2Z
Equinor ASA |
+0.598 0.237% | 254.525 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 |
|
0VSO
BYD Co. Ltd. |
-2.605 7.316% | 33.09 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 |
Income Statement
(Currency in GBP)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Income Before Tax | 22.314M | 6.665M | -57.263M | 5.29M | 17.498M |
| Minority Interest | - | - | - | - | - |
| Net Income | 18.427M | 8.152M | -43.735M | 4.939M | 12.685M |
| Selling General Administrative | 62.579M | 55.687M | 31.988M | 24.739M | 69.083M |
| Gross Profit | 296.956M | 188.279M | 129.73M | 162.813M | 135.953M |
| Reconciled Depreciation | - | - | - | - | - |
| Ebit | 12.854M | -18.742M | -44.186M | 3.971M | 13.48M |
| Ebitda | 21.702M | -11.7M | -36.605M | 11.741M | - |
| Depreciation And Amortization | 8.848M | 7.042M | 7.581M | 7.77M | - |
| Operating Income | 12.854M | -18.742M | -44.186M | 3.971M | 14M |
| Other Operating Expenses | 394.496M | 251.445M | 236.843M | 215.731M | 4.075M |
| Interest Expense | - | 0M | 0M | 0M | 0M |
| Tax Provision | - | -1.487M | -13.528M | 0.351M | 4.813M |
| Interest Income | - | 25.163M | 11.387M | 1.414M | 3.584M |
| Net Interest Income | - | - | - | - | - |
| Income Tax Expense | 3.887M | 1.487M | 13.528M | 0.351M | 4.813M |
| Total Revenue | 415.292M | 258.386M | 179.861M | 220.837M | 187.868M |
| Total Operating Expenses | 276.16M | 181.338M | 186.712M | 157.707M | - |
| Cost Of Revenue | 118.336M | 70.107M | 50.131M | 58.024M | 51.915M |
| Total Other Income Expense Net | 9.46M | 25.407M | -13.077M | 1.319M | - |
| Net Income From Continuing Ops | - | - | - | - | - |
| Net Income Applicable To Common Shares | 18.427M | 8.152M | -43.735M | 4.939M | 12.685M |
Balance Sheet
(Currency in GBP)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Total Assets | 1733.084M | 1542.596M | 1150.309M | 634.487M | 586.612M |
| Intangible Assets | 8.485M | 8.658M | 6.75M | 6.219M | 214.084M |
| Other Current Assets | 19.897M | 19.21M | 9.46M | 12.343M | - |
| Total Liab | 302.948M | 257.146M | 141.848M | 56.966M | 46.135M |
| Total Stockholder Equity | 1430.136M | 1285.45M | 1008.461M | 577.521M | 540.477M |
| Other Current Liab | 96.427M | 83.074M | 57.78M | 38.193M | 3.756M |
| Common Stock | 0.762M | 0.754M | 0.734M | 0.68M | 0.675M |
| Capital Stock | - | - | - | - | - |
| Retained Earnings | 27.753M | 9.277M | 1.125M | 44.86M | 39.921M |
| Good Will | 625.319M | 460.228M | 223.938M | 65.773M | 65.614M |
| Other Assets | 583.782M | 498.722M | 434.303M | 278.833M | 224.008M |
| Cash | 246.545M | 398.696M | 354.236M | 159.946M | 187.064M |
| Cash And Equivalents | - | - | - | - | - |
| Total Current Liabilities | 134.896M | 104.519M | 72.248M | 52.599M | 42.573M |
| Current Deferred Revenue | - | - | - | - | - |
| Net Debt | -246.545M | -398.696M | -354.236M | -159.946M | - |
| Short Term Debt | - | - | - | - | - |
| Short Long Term Debt | - | - | - | - | - |
| Short Long Term Debt Total | - | 1.522M | 3.286M | 2.154M | - |
| Other Stockholder Equity | 1401.621M | 1275.419M | 1006.602M | 531.981M | 13.021M |
| Property Plant Equipment | 47.579M | 26.297M | 21.334M | 23.554M | 15.615M |
| Total Current Assets | 467.508M | 547.532M | 463.23M | 259.885M | 277.68M |
| Long Term Investments | - | - | - | - | - |
| Short Term Investments | - | - | - | - | - |
| Net Receivables | 94.5M | 52.036M | 40.183M | 43.725M | 46.925M |
| Long Term Debt | - | 1.522M | 3.286M | 2.154M | - |
| Inventory | 106.566M | 77.59M | 59.351M | 43.871M | 36.387M |
| Accounts Payable | 38.469M | 21.445M | 14.468M | 14.406M | 16.333M |
| Accumulated Other Comprehensive Income | - | - | - | - | - |
| Non Currrent Assets Other | -681.794M | -496.342M | -252.776M | -95.769M | - |
| Non Current Assets Total | 681.794M | 496.342M | 252.776M | 95.769M | - |
| Capital Lease Obligations | - | - | - | - | - |
| Long Term Debt Total | - | - | - | - | - |
Cash Flow
(Currency in GBP)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Investments | - | -0.401M | -0.536M | -0.151M | -0.151M |
| Total Cashflows From Investing Activities | -197.624M | -187.703M | -266.532M | -83.844M | -53.198M |
| Total Cash From Financing Activities | -6.842M | 234.611M | 482.768M | 25.551M | 19.204M |
| Net Income | 18.427M | 8.152M | -43.735M | 4.939M | 12.685M |
| Change In Cash | -152.151M | 44.46M | 194.29M | -27.118M | -8.258M |
| Begin Period Cash Flow | 398.696M | 354.236M | 159.946M | 187.064M | - |
| End Period Cash Flow | 246.545M | 398.696M | 354.236M | 159.946M | 187.064M |
| Total Cash From Operating Activities | 27.856M | -12.059M | -12.266M | 29.505M | 23.627M |
| Depreciation | 15.228M | 11.884M | 13.248M | 11.119M | 6.766M |
| Other Cashflows From Investing Activities | 0.776M | -0.403M | -0.632M | -0.632M | -0.632M |
| Dividends Paid | - | - | - | - | - |
| Change To Inventory | -6.325M | -13.802M | -14.155M | -8.478M | -2.976M |
| Sale Purchase Of Stock | - | - | 488.435M | 28.9M | 19.204M |
| Other Cashflows From Financing Activities | 0.447M | 245.353M | 488.435M | 28.9M | 0.182M |
| Capital Expenditures | 18.185M | 10.194M | 2.631M | 10.503M | 6.662M |
| Change In Working Capital | -33.185M | -22.096M | 6.429M | -9.02M | -9.798M |
| Other Non Cash Items | 20.699M | -12.601M | -6.468M | 15.421M | - |
| Free Cash Flow | 9.671M | -22.253M | -14.897M | 19.002M | - |
No data found
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
Related Articles
Loading...
